Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Randomized Study Comparing the Biological Efficacy & Safety of a New Prolonged Release Formulation of Octreotide Acetate, C2L-OCT-01 PR, 30 mg Administered Every 42 Days for 84 Days With Sandostatin LAR 30 mg Administered Every 28 Days for 84 Days to Acromegalic Patients

NCT00616551 is registered in ClinicalTrials.gov with Ambrilia Biopharma, Inc. as lead sponsor.

NCT NCT00616551
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00616551 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Randomized Study Comparing the Biological Efficacy & Safety of a New Prolonged Release Formulation of Octreotide Acetate, C2L-OCT-01 PR, 30 mg Administered Every 42 Days for 84 Days With Sandostatin LAR 30 mg Administered Every 28 Days for 84 Days to Acromegalic Patients
Lead sponsor
Ambrilia Biopharma, Inc.
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2007
Completion date
February 29, 2008
Enrollment
65 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

acromegaly